This is a Single Ascending Dose Tolerance Study
NCT01133574 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 47
Last updated 2011-08-29
Summary
This is a single rising dose tolerance (Part A) followed by a functional magnetic resonance imaging (Part B)
Conditions
- Cognition Disorders
Interventions
- DRUG
-
SLV354 capsules
20 mg
- DRUG
-
SLV354 capsules
60 mg
- DRUG
-
SLV354 capsules
120 mg
- DRUG
-
SLV354 capsules
250 mg
- DRUG
-
SLV354 capsules
500 mg
- DRUG
-
SLV354 capsules
750 mg
- DRUG
-
SLV354 capsules
1000 mg
- DRUG
-
SLV354 capsules
1250 mg
- DRUG
-
Placebo capsules
placebo
- DRUG
-
SLV354 capsules
low dose group 1
- DRUG
-
SLV354 capsules
high dose group 1
- DRUG
-
SLV354 capsules
low dose group 2
- DRUG
-
SLV354 capsules
high dose group 2
- DRUG
-
Placebo capsules
placebo
Sponsors & Collaborators
-
Quintiles, Inc.
collaborator INDUSTRY - lead INDUSTRY
Principal Investigators
-
Beatrice Rendenbach-Mueller, PhD · Abbott
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2010-02-28
- Primary Completion
- 2010-07-31
- Completion
- 2010-07-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including an Assessment of Receptor Occupancy and Food Effect
NCT05486195 ·Status: COMPLETED ·Phase: PHASE1
-
A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease
NCT00890890 ·Status: TERMINATED ·Phase: PHASE2
-
A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects
NCT01221259 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
NCT05771428 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)
NCT03720548 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
NCT03131453 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
NCT05231785 ·Status: RECRUITING ·Phase: PHASE1
-
Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease
NCT00555204 ·Status: TERMINATED ·Phase: PHASE2
-
Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease
NCT00501111 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy
NCT04958031 ·Status: TERMINATED ·Phase: PHASE2
-
Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment
NCT02573740 ·Status: TERMINATED ·Phase: PHASE1
-
Study of LM11A-31-BHS in Mild-moderate AD Patients
NCT03069014 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance
NCT03980730 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease
NCT00359944 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects
NCT04251182 ·Status: COMPLETED ·Phase: PHASE2
-
An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease
NCT01013610 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia
NCT00099216 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease
NCT00736775 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants
NCT01887535 ·Status: COMPLETED ·Phase: PHASE1
-
Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease
NCT03008161 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease
NCT03352557 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
NCT03305809 ·Status: COMPLETED ·Phase: PHASE2
-
An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.
NCT00301574 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms
NCT02626572 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease
NCT00459550 ·Status: COMPLETED ·Phase: PHASE1